特发性肺动脉高压患者RDW、NT-ProBNP、BigET-1、HMGB1水平变化及临床意义

doi:10.3969/j.issn.1004-583X.2021.11.008

摘要/Abstract

摘要：

目的探讨特发性肺动脉高压(IPAH)患者红细胞分布宽度(RDW)、N-端脑钠肽前体(NT-proBNP)、大内皮素-1(BigET-1)以及高迁移率组蛋白B1(HMGB1)的变化及临床意义。方法选取我院2019年11月至2020年10月收治的IPAH患者80例为观察组,另选取同期在我院体检的健康人80例为对照组,对比两组RDW、NT-proBNP、BigET-1、HMGB1以及超声心动图指标,并分析上述指标的相关性。结果观察组RDW、NT-proBNP、BigET-1、HMGB1均高于对照组(均P<0.01);左心室舒张末期内径(LVEDD小于对照组(P<0.01);RVEDD大于对照组(P<0.01)。相关分析表明,IPAH患者RDW、NT-proBNP、BigET-1、HMGB1与LVEDD、左心室射血分数(LVEF)、心脏指数(CI)呈负相关,与RVEDD呈正相关;NT-proBNP、HMGB1均与肺动脉平均压(PAMP)、肺血管阻力(PVR)呈正相关(P<0.05)。结论 RDW、NT-proBNP、BigET-1、HMGB1水平在IPAH患者中明显升高,且与LVEDD、PAMP、PVR等指标相关,可作为诊断与评估IPAH病情的参考指标。

关键词: 家族性原发性肺动脉高压, 大内皮素-1, 高迁移率组蛋白B1, 生化指标

Abstract:

Objective To explore the changes and clinical significance of red blood cell distribution width(RDW), N-terminal pro-brain natriuretic peptide(NT-proBNP), big endothelin-1(BigET-1), high mobility group protein-B1(HMGB1) in patients with idiopathic pulmonary arterial hypertension(IPAH).Methods Totally 80 IPAH patients admitted to our hospital from Nov 2019 to Oct 2020 were enrolled as the observation group,the control group comprised 80 healthy volunteers undergoing physical examination in our hospital during the same period; the aim was to compare RDW, NT-proBNP, BigET-1, HMGB1 as well as echocardiogram indexes between groups; and the correlation of the above indicators was analyzed. Results Compared with control group, RDW, NT-proBNP, BigET-1, HMGB1 in observation group were significantly higher (all P<0.01), left ventricular end diastolic dimension(LVEDD) was notably smaller (P<0.01), right ventricular end diastolic diameter(RVEDD) was significantly larger (P<0.01). Correlation analysis showed that RDW, NT-proBNP, BigET-1, HMGB1 were negatively correlated with LVEDD, left ventricle ejection fraction(LVEF), cardiac index(CI), while positively correlated with RVEDD. Positive correlation existed between NT-proBNP, HMGB1 and pulmonary artery mean pressure(PAMP), pulmonary vascular resistance(PVR)(P<0.05).Conclusion RDW, Nt-proBNP, BigET-1, HMGB1 in IPAH patients are increased, and the indexes are related to LVEDD, PAMP, PVR, and those can be used as references for diagnosis and evaluation of IPAH.

Key words: familial primary pulmonary hypertension, big endothelin-1, high mobility group protein-B1, biochemical index

中图分类号:

R544.16

安勤燕, 姜蓉, 康彬, 杜明, 周仁明, 赵洪娟, 段炜, 卢飞, 刘锦铭. 特发性肺动脉高压患者RDW、NT-ProBNP、BigET-1、HMGB1水平变化及临床意义[J]. 临床荟萃, 2021, 36(11): 1001-1004.

An Qinyan, Jiang Rong, Kang Bin, Du Ming, Zhou Renming, Zhao Hongjuan, Duan Yi, Lu Fei, Liu Jinming. Levels and clinical significance of RDW, NT-proBNP, BigET-1, HMGB1 in patients with idiopathic pulmonary arterial hypertension[J]. Clinical Focus, 2021, 36(11): 1001-1004.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2021.11.008

https://huicui.hebmu.edu.cn/CN/Y2021/V36/I11/1001

图/表 4

参考文献 21

[1]	范粉灵, 张松林, 宋强, 等. “3P”路径诊断特发性肺动脉高压[J]. 中华心血管病杂志, 2020, 48(7):621-625.
[2]	崔宇菲, 张磊, 叶岚. 肺动脉高压基因遗传突变研究进展[J]. 疑难病杂志, 2020, 19(7):739-742.
[3]	Lappegård J, Ellingsen TS, Skjelbakken T, et al. Red cell distribution width is associated with future risk of incident stroke. The Tromsø Study[J]. Thromb Haemost, 2017, 115(1):126-134. doi: 10.1160/TH15-03-0234 URL
[4]	Jia J, Chang GL, Qin S, et al. Comparative evaluation of copeptin and NT-proBNP in patients with severe acute decompensated heart failure,and prediction of adverse events in a 90 day follow-up period:A prospective clinical observation trial[J]. Exp Ther Med, 2017, 13(4):1554-1560. doi: 10.3892/etm.2017.4111 URL
[5]	Chen Y, Li JX, Song Y, et al. Plasma big endothelin-1 and stent thrombosis: An observational study in patients undergoing percutaneous coronary intervention in China[J]. Thromb Res, 2017, 159:5-12. doi: S0049-3848(17)30491-7 pmid: 28942357
[6]	Jiang M, Li XL, Quan XW, et al. Single nucleotide polymorphisms in HMGB1 correlate with lung cancer risk in the northeast Chinese Han population[J]. Molecules, 2018, 23(4):832. doi: 10.3390/molecules23040832 URL
[7]	中国肺动脉高压诊断与治疗指南(2021版)[J]. 中华医学杂志, 2021, 101(1):11-51.
[8]	余洪, 汪云鑫, 李品慧, 等. 急性ST段抬高性心肌梗死红细胞分布宽度血小板比率的变化及其与远期心血管事件的关系[J]. 中华保健医学杂志, 2020, 22(3):150-153.
[9]	袁胜芳, 宋宁, 王布, 等. 红细胞分布宽度联合血清胱抑素C早期诊断慢性阻塞性肺疾病继发肺动脉高压的价值[J]. 河北医科大学学报, 2020, 41(6):624-627, 631.
[10]	黄丽, 何建国. 肺动脉高压与铁缺乏[J]. 中华医学杂志, 2016, 96(16):1304-1306.
[11]	潘碧云, 伍羿, 陈仕银等. 红细胞分布宽度预测急性呼吸困难患者30天病死率的价值研究[J]. 中国急救医学, 2020, 40(1):29-34.
[12]	Darche FF, Baumg-Rtner C, Biener M, et al. Comparative accuracy of NT-proBNP and MR-proANP for the diagnosis of acute heart failure in dyspnoeic patients[J]. Esc Hean Failure, 2017, 4(3):232-240.
[13]	Olivier A, Girerd N, Michel JB, et al. Combined baseline and one-month changes in big endothelin-1 and brain natriuretic peptide plasma concentrations predict clinical outcomes in patients with left ventricular dysfunction after acute myocardial infarction:Insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study( EPHESUS) study[J]. Int J Cardiol, 2017, 241:344-350. doi: S0167-5273(16)32115-5 pmid: 28284500
[14]	Gaggin HK, Truong QA, Gandhi PU, et al. Systematic evaluation of Endothelin 1 measurement relative to traditional and modern biomarkers for clinical assessment and prognosis in patients with chronic systolic heart failure: serial measurement and multimarker testing[J]. Am J Clin Pathol, 2017, 147(5):461-472. doi: 10.1093/ajcp/aqx014 pmid: 28398455
[15]	马凤英, 卢卫娜. 先天性心脏病合并肺动脉高压患儿内源性二氧化硫、内皮素-1、同型半胱氨酸水平及其相关性分析[J]. 临床误诊误治, 2020, 33(7):58-61.
[16]	刘晓琳, 杨登魁, 江水明, 等. 肺动脉高压合并细菌感染患者ET-1水平的变化及与预后的关系[J]. 检验医学与临床, 2020, 17(6):765-767, 771.
[17]	刘洋. 苓桂术甘汤联合福辛普利对伴有肺动脉高压的慢性肺原性心脏病患者右心室肥厚、 NT-proBNP、ET-1的影响[J]. 河北中医药学报, 2019, 34(4):45-48.
[18]	范志茹, 倪欣, 单莉娅, 等. 肺动脉高压大鼠肺部炎症与CD4+T淋巴细胞上Cx40、Cx43的相关性研究[J]. 中国免疫学杂志, 2019, 35(9):1031-1035, 1041.
[19]	尧小龙, 蒋倩, 丁卫, 等. 白介素-4抑制HMGB1介导的小胶质细胞NLRP3炎症复合体形成的机制研究[J]. 中华神经医学杂志, 2018, 17(4):364-370.
[20]	何姗姗, 余娅, 高进, 等. 右侧颈交感干离断对大鼠心肌梗死后炎症反应的抑制作用及对HMGB1/TLR4/NF-κB通路的影响[J]. 中国病理生理杂志, 2018, 34(3):403-409.
[21]	戴耄. 高迁移率族蛋白B1在低氧及野百合碱所致肺动脉高压大鼠模型中的作用及机制[D]. 华中科技大学, 2018.

组别	例数	性别[例(%)]		年龄 (岁)	BMI (kg/m²)	HR (次/min)	SBP (mmHg)	DBP (mmHg)
组别	例数	男	女	年龄 (岁)	BMI (kg/m²)	HR (次/min)	SBP (mmHg)	DBP (mmHg)
观察组	80	32(40.00)	48(60.00)	42.54±8.22	22.48±2.74	81.48±9.73	115.72±10.49	73.89±7.27
对照组	80	34(42.50)	46(57.50)	41.94±7.90	23.23±2.58	78.79±8.45	116.88±11.52	75.59±7.21
t/χ²值		0.103		0.471	1.782	1.867	0.666	1.116
P值		0.748		0.638	0.077	0.064	0.506	0.266

组别	例数	性别[例(%)]		年龄 (岁)	BMI (kg/m²)	HR (次/min)	SBP (mmHg)	DBP (mmHg)
组别	例数	男	女	年龄 (岁)	BMI (kg/m²)	HR (次/min)	SBP (mmHg)	DBP (mmHg)
观察组	80	32(40.00)	48(60.00)	42.54±8.22	22.48±2.74	81.48±9.73	115.72±10.49	73.89±7.27
对照组	80	34(42.50)	46(57.50)	41.94±7.90	23.23±2.58	78.79±8.45	116.88±11.52	75.59±7.21
t/χ²值		0.103		0.471	1.782	1.867	0.666	1.116
P值		0.748		0.638	0.077	0.064	0.506	0.266

组别	例数	RDW (%)	NT-proBNP (pmol/L)	BigET-1 (ng/L)	HMGB1 (μg/L)
观察组	80	14.86±1.38	1546.53±239.89	1.13±0.62	14.77±2.34
对照组	80	13.12±1.23	289.22±41.24	0.38±0.46	4.04±1.32
t值		8.419	46.201	8.689	35.722
P值		<0.01	<0.01	<0.01	<0.01

组别	例数	RDW (%)	NT-proBNP (pmol/L)	BigET-1 (ng/L)	HMGB1 (μg/L)
观察组	80	14.86±1.38	1546.53±239.89	1.13±0.62	14.77±2.34
对照组	80	13.12±1.23	289.22±41.24	0.38±0.46	4.04±1.32
t值		8.419	46.201	8.689	35.722
P值		<0.01	<0.01	<0.01	<0.01

组别	例数	LVEDD(mm)	RVEDD(mm)	LVEF(%)
观察组	80	33.13±6.83	47.42±8.64	67.32±5.92
对照组	80	42.24±4.78	35.21±4.59	66.16±5.59
t值		9.774	11.163	1.274
P值		<0.01	<0.01	0.204